公开(公告)号：US20190153113A1

公开(公告)日：2019-05-23

申请号：US15778202

申请日：2016-11-22

Applicant: INNATE PHARMA ,  OREGA BIOTECH

Inventor： Jérémy BASTID ,  Laurent GAUTHIER ,  Carine PATUREL ,  Ivan PERROT ,  Alain ROUSSEL ,  Béatrice AMIGUES

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to antigen-binding compounds that inhibit CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g. cancer.

公开(公告)号：US20160369002A1

公开(公告)日：2016-12-22

申请号：US15190337

申请日：2016-06-23

Applicant: INNATE PHARMA

Inventor： Laurent GAUTHIER ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: C07K16/28

CPC classification number: C07K16/2896 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/283 ,  C07K16/2866 ,  C07K16/2887 ,  C07K2317/31 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2319/30 ,  A61K39/001102 ,  A61K39/001104

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

Abstract translation: 在不存在靶细胞的情况下，提供结合并特异性地重定向NK细胞以裂解感兴趣的靶细胞的多特异性蛋白质而没有NK细胞的非特异性激活。 这些蛋白质可用于治疗疾病，特别是癌症或感染性疾病。